Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Vaccines

Free Subscription Articles published in J Virol Retrieve available abstracts of 197 articles: HTML format

Single Articles

October 2026
1. SUN J, Wang J, Li K, Wei D, et al
   Generation and characterization of a PRRSV-2 DIVA marker virus by deletion of a novel epitope in the nucleocapsid protein.
   J Virol. 2026;100:e0125926.
   PubMed     Abstract available
   
   
   
2. ZHANG Q-Y, Zhang Z-R, Deng C-L, Wang J, et al
   Internal poly(A) replacement strategy within 3' UTR for live-attenuated tick-borne encephalitis virus.
   J Virol. 2026;100:e0078126.
   PubMed     Abstract available
   
   
   
3. CIACCI ZANELLA G, Vincent ML, Flores L, Aljets EK, et al
   A multivalent mRNA-lipid nanoparticle vaccine containing eight hemagglutinin antigens elicited broad neutralizing antibody responses and protected against influenza A virus challenge in swine.
   J Virol. 2026 Oct 9:e0084826. doi: 10.1128/jvi.00848.
   PubMed     Abstract available
   
   
   
4. SOUZA CK, Santos JJS, Boggiatto P, Sterle H, et al
   H5 influenza virus mRNA-lipid nanoparticle (LNP) vaccination elicits adaptive immune responses in Holstein calves.
   J Virol. 2026 Oct 8:e0128926. doi: 10.1128/jvi.01289.
   PubMed     Abstract available
   
   
   
5. DEL ROSARIO JMM, van Diemen PM, Frost SDW, Vishwanath S, et al
   A digitally immune-optimized influenza vaccine broadly neutralizes swine and human H1N1 influenza viruses and protects from heterologous challenge.
   J Virol. 2026 Oct 6:e0107326. doi: 10.1128/jvi.01073.
   PubMed     Abstract available
   
   
   
6. SILVA MARINHO PE, Ghimire D, Tsai Silva J, Devlin J, et al
   Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolates.
   J Virol. 2026 Oct 5:e0122126. doi: 10.1128/jvi.01221.
   PubMed     Abstract available
   
   
   
7. ZHANG Y, Duan Y, Shi L, Zhu X, et al
   A live PRV-vectored bivalent vaccine elicits dual protection against pseudorabies virus and swine acute diarrhea syndrome coronavirus.
   J Virol. 2026 Oct 5:e0119326. doi: 10.1128/jvi.01193.
   PubMed     Abstract available
   
   
   September 2026
8. ZHANG Y, Holly J, Gibbs J, Yewdell JW, et al
   Real-time tracking of vaccinia virus entry using a split luciferase complementation assay.
   J Virol. 2026 Sep 29:e0111526. doi: 10.1128/jvi.01115.
   PubMed     Abstract available
   
   
   
9. PARK H-S, Matsuoka Y, Santos C, Duncan EF, et al
   Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters.
   J Virol. 2026 Sep 24:e0093826. doi: 10.1128/jvi.00938.
   PubMed     Abstract available
   
   
   
10. PETCH RJ, Hicks P, Westover JB, Gowen BB, et al
    Mutations that positively affect Bandavirus glycoprotein function in VSV-vectored vaccines.
    J Virol. 2026 Sep 24:e0131126. doi: 10.1128/jvi.01311.
    PubMed     Abstract available
    
    
    
11. KIRK J, Sives S, Rayment A, Tappin A, et al
    Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.
    J Virol. 2026 Sep 10:e0110326. doi: 10.1128/jvi.01103.
    PubMed     Abstract available
    
    
    
12. BHAVSAR D, Civljak A, Bonnettaz B, Arunkumar GA, et al
    Broadly reactive antibodies against influenza B virus hemagglutinin neutralize and protect through distinct structural mechanisms.
    J Virol. 2026 Sep 4:e0080226. doi: 10.1128/jvi.00802.
    PubMed     Abstract available
    
    
    August 2026
13. KUMAR S, Lai L, Ellis ML, Patel A, et al
    Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.
    J Virol. 2026 Aug 26:e0074926. doi: 10.1128/jvi.00749.
    PubMed     Abstract available
    
    
    
14. ALVAREZ J, Olczak P, Tsai H-L, Terrell J, et al
    Factors impacting protective immunity conferred by vaccination with adeno-associated virus-like particles displaying human papillomavirus L2 residues 17-36.
    J Virol. 2026 Aug 21:e0044826. doi: 10.1128/jvi.00448.
    PubMed     Abstract available
    
    
    
15. PALANDE V, Zhang T, Smith KN, Levinson K, et al
    Exploration of immune correlates of viral clearance after PVX2 immunotherapy in patients with human papillomavirus type 16 infection and cervical intraepithelial neoplasia grade
    J Virol. 2026;100:e0064326.
    PubMed     Abstract available
    
    
    
16. ZHENG M, Pan Z, Jiang Y, Guo Y, et al
    A nanoluciferase-expressing attenuated CHIKV vaccine strain enables rapid and visual drug screening in vitro and in vivo.
    J Virol. 2026 Aug 11:e0046626. doi: 10.1128/jvi.00466.
    PubMed     Abstract available
    
    
    July 2026
17. REN J, Liu S, Yuan H, Wu Y, et al
    Enhanced replication and immunogenicity of a genome-modified non-replicating vaccinia virus Tiantan strain for robust low-dose protection in mice.
    J Virol. 2026 Jul 31:e0094326. doi: 10.1128/jvi.00943.
    PubMed     Abstract available
    
    
    
18. FARRIS L, Watts J, Pollet J, Molter C, et al
    Evaluation of a multiantigen mRNA vaccine against EEHV1A in Asian elephants.
    J Virol. 2026 Jul 28:e0038826. doi: 10.1128/jvi.00388.
    PubMed     Abstract available
    
    
    
19. WENNINGER M, Farris L, Heinz J, Peng R, et al
    First evidence of clinical protection from an EEHV1A mRNA vaccine in naturally infected juvenile elephants.
    J Virol. 2026 Jul 28:e0218625. doi: 10.1128/jvi.02186.
    PubMed     Abstract available
    
    
    
20. DWIVEDI S, Kar S, Horton AP, Gollihar JD, et al
    ViralMap: predicting features in viral proteins from primary sequence.
    J Virol. 2026 Jul 28:e0075726. doi: 10.1128/jvi.00757.
    PubMed     Abstract available
    
    
    
21. KING HAD, Subra C, Tourtellott E, Swafford I, et al
    Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates.
    J Virol. 2026 Jul 27:e0038926. doi: 10.1128/jvi.00389.
    PubMed     Abstract available
    
    
    
22. ERICKSON R, Bates P
    Immunogenicity of recombinant vesicular stomatitis virus-vectored vaccines expressing the Machupo virus glycoprotein in different genome positions.
    J Virol. 2026 Jul 24:e0035726. doi: 10.1128/jvi.00357.
    PubMed     Abstract available
    
    
    
23. BEETON K, Case JB
    Respiratory mucosal vaccines for emerging viruses: promise and challenges.
    J Virol. 2026 Jul 23:e0174825. doi: 10.1128/jvi.01748.
    PubMed     Abstract available
    
    
    
24. CHATTERJEE A, Mangala Prasad V
    Role of quaternary epitopes in eliciting broad neutralization response against multiple flaviviruses.
    J Virol. 2026;100:e0177725.
    PubMed     Abstract available
    
    
    
25. ZHANG Q-Y, Zhang Y, Zhang Z-R, Li Y, et al
    A single-dose chimeric Newcastle disease virus (NDV)/chikungunya virus (CHIKV) is an effective CHIKV vaccine candidate.
    J Virol. 2026 Jul 10:e0056826. doi: 10.1128/jvi.00568.
    PubMed     Abstract available
    
    
    
26. LAMICHHANE P, Yang L, Santos C, Park H-S, et al
    Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus.
    J Virol. 2026 Jul 6:e0069226. doi: 10.1128/jvi.00692.
    PubMed     Abstract available
    
    
    
27. CHIU H-J, Carillo KJ, Hsieh LT-H, Lou Y-C, et al
    Structure and functional analyses of vaccinia virus J5 protein reveal distinct determinants for entry-fusion complex assembly and activation.
    J Virol. 2026 Jul 6:e0037926. doi: 10.1128/jvi.00379.
    PubMed     Abstract available
    
    
    
28. TIWAREKAR V, Ebenig A, Predota Y, Schrauf S, et al
    Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigen.
    J Virol. 2026 Jul 1:e0064426. doi: 10.1128/jvi.00644.
    PubMed     Abstract available
    
    
    June 2026
29. CALLAWAY HM
    Structural overview of lyssavirus glycoproteins, antibodies, and receptors.
    J Virol. 2026;100:e0178625.
    PubMed     Abstract available
    
    
    
30. AO Z, Vendramelli R, Buyu M, Truong T, et al
    A VSV-vector vaccine simultaneously targeting H5N1 hemagglutinin and matrix protein 2 induces robust neutralizing and ADCC antibody responses and provides full protection against lethal H5N1 infection in a mouse model.
    J Virol. 2026 Jun 16:e0009726. doi: 10.1128/jvi.00097.
    PubMed     Abstract available
    
    
    
31. JACKSON N, Bayoumi M, Nath H, Martinez-Sobrido L, et al
    Fluorescent protein-expressing Modified Vaccinia Ankara encoding T7 RNA polymerase.
    J Virol. 2026 Jun 12:e0075526. doi: 10.1128/jvi.00755.
    PubMed     Abstract available
    
    
    
32. ZHAI H, Gao Y, Wan N, Qu Y, et al
    A ubiquitinated E2-based mRNA vaccine confers complete protection against lethal challenge with classical swine fever virus.
    J Virol. 2026 Jun 12:e0026926. doi: 10.1128/jvi.00269.
    PubMed     Abstract available
    
    
    
33. XU S, Zhang Q, Xie X, Zhou M, et al
    A neutralizing nanobody targeting a conserved lateral patch on HA1 confers protection against multiple H7 avian influenza viruses.
    J Virol. 2026 Jun 11:e0056326. doi: 10.1128/jvi.00563.
    PubMed     Abstract available
    
    
    
34. WANG L, Shen J
    Progress in enterovirus D68-neutralizing antibodies and vaccines.
    J Virol. 2026 Jun 3:e0012326. doi: 10.1128/jvi.00123.
    PubMed     Abstract available
    
    
    May 2026
35. LOES AN, Tarabi RAL, Li SH, Atkinson RK, et al
    Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines.
    J Virol. 2026 May 27:e0031726. doi: 10.1128/jvi.00317.
    PubMed     Abstract available
    
    
    
36. ZHOU C, Cheng M-L, He M-J, Liu Y, et al
    MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy.
    J Virol. 2026 May 15:e0020826. doi: 10.1128/jvi.00208.
    PubMed     Abstract available
    
    
    
37. VAN PUL L, Rosendahl Huber SK, Jacobi R, Hendriks M, et al
    Cross-reactive antibody and T-cell responses after influenza virus infection in community-dwelling older adults.
    J Virol. 2026 May 12:e0040726. doi: 10.1128/jvi.00407.
    PubMed     Abstract available
    
    
    
38. JIANG S, Cui J, Sun T, Li J, et al
    A chimeric trivalent Echovirus vaccine designed by loop substitution elicits cross-neutralizing immunity against serotypes 11, 18, and 30.
    J Virol. 2026 May 5:e0045726. doi: 10.1128/jvi.00457.
    PubMed     Abstract available
    
    
    April 2026
39. DAINES R, Sadeyen J-R, Chang P, Iqbal M, et al
    Mapping hemagglutinin residues driving antigenic diversity in H5Nx avian influenza viruses.
    J Virol. 2026 Apr 30:e0009526. doi: 10.1128/jvi.00095.
    PubMed     Abstract available
    
    
    
40. LIU K, Liu Z, Yan X, Yang Z, et al
    A single residue in the VP3 capsid protein governs virulence and informs live-attenuated vaccine design for coxsackievirus A6.
    J Virol. 2026 Apr 27:e0014926. doi: 10.1128/jvi.00149.
    PubMed     Abstract available
    
    
    
41. HENG W, Zhou Z, Lin W, Zhang X, et al
    A novel replication-deficient feline herpesvirus type 1 vector-based vaccine provides strong immune protection in cats.
    J Virol. 2026 Apr 27:e0218825. doi: 10.1128/jvi.02188.
    PubMed     Abstract available
    
    
    
42. NASIR A, Lee D, Avena LE, Berrueta DM, et al
    Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants.
    J Virol. 2026 Apr 27:e0022526. doi: 10.1128/jvi.00225.
    PubMed     Abstract available
    
    
    
43. YANG M, Zhao Y, Guo W, Wang L, et al
    Development of a vaccine based on mRNA assembly of PEDV virus-like particle.
    J Virol. 2026 Apr 21:e0206025. doi: 10.1128/jvi.02060.
    PubMed     Abstract available
    
    
    
44. SINGH S, Kumar S, Luthra K
    Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.
    J Virol. 2026 Apr 21:e0220225. doi: 10.1128/jvi.02202.
    PubMed     Abstract available
    
    
    
45. SONI S, Eertink LG, Shuisong N, Loynachan A, et al
    Cross-neutralization and antigenic characterization of simian and equine group A rotaviruses.
    J Virol. 2026;100:e0019926.
    PubMed     Abstract available
    
    
    
46. CHENG X, Deng H, Bian X, Wang J, et al
    Simultaneous expression of three G genotypes of VP7 proteins in a recombinant porcine rotavirus confers protective immunity against multiple rotavirus infections.
    J Virol. 2026;100:e0201525.
    PubMed     Abstract available
    
    
    
47. YILDIZ S, El Zahed SS, Villalon-Letelier F, Wang Q, et al
    Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.
    J Virol. 2026 Apr 21:e0034726. doi: 10.1128/jvi.00347.
    PubMed     Abstract available
    
    
    
48. TANG PCH, Ling Z, Lee M, King NJC, et al
    Combating respiratory diseases with mucosal vaccines.
    J Virol. 2026 Apr 15:e0014626. doi: 10.1128/jvi.00146.
    PubMed     Abstract available
    
    
    March 2026
49. KIM K-H, Hwang HS, Pal SS, Tien Le CT, et al
    Type I interferon signaling is required for resistance to primary influenza virus infection and vaccine-induced long-term immunity.
    J Virol. 2026 Mar 27:e0022926. doi: 10.1128/jvi.00229.
    PubMed     Abstract available
    
    
    
50. WANG J, Chang J, Jiang Z, Deng H, et al
    An oral rotavirus-vectored vaccine confers protection against Clostridium perfringens and rotavirus.
    J Virol. 2026 Mar 26:e0017826. doi: 10.1128/jvi.00178.
    PubMed     Abstract available
    
    
    February 2026
51. PARRA GI, Ford-Siltz LA, Pilewski KA, Tohma K, et al
    Variable and conserved B cell epitopes of GII.4 human noroviruses.
    J Virol. 2026;100:e0180425.
    PubMed     Abstract available
    
    
    
52. PATEL J, Yang Z, Ping S, Ahmed A, et al
    The magnitude and durability of neutralizing antibody responses to human papillomavirus vaccine do not depend on DNA sensing pathways.
    J Virol. 2026 Feb 10:e0215025. doi: 10.1128/jvi.02150.
    PubMed     Abstract available
    
    
    January 2026
53. SU W, Zhao T, Ren X, Li S, et al
    Protective efficacy of a genetically modified attenuated vaccinia virus Tiantan strain against monkeypox virus challenge in a small animal model.
    J Virol. 2026 Jan 27:e0184325. doi: 10.1128/jvi.01843.
    PubMed     Abstract available
    
    
    
54. BRIGLEB PH, Sharp B, Lazure L, Livingston B, et al
    Immune history confers antibody- and T cell-dependent cross-protection against highly pathogenic avian influenza H5N1 viruses.
    J Virol. 2026 Jan 22:e0208825. doi: 10.1128/jvi.02088.
    PubMed     Abstract available
    
    
    
55. CONG G, Li H, Li L, Chen J, et al
    The newly developed porcine-origin parainfluenza virus PIV5-JS17 serves as an exogenous gene delivery system for swine.
    J Virol. 2026 Jan 13:e0185825. doi: 10.1128/jvi.01858.
    PubMed     Abstract available
    
    
    
56. SIEVERS BL, Hyder S, Chan M, Ly S, et al
    Measles vaccination perceptions and willingness to consider novel vaccination approaches in Cambodia's floating villages.
    J Virol. 2026 Jan 7:e0171825. doi: 10.1128/jvi.01718.
    PubMed     Abstract available
    
    
    
57. HAZELL NC, Reyna RA, Adam A, Bonam SR, et al
    mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models.
    J Virol. 2026 Jan 7:e0189725. doi: 10.1128/jvi.01897.
    PubMed     Abstract available
    
    
    December 2025
58. ZHAO Y, Ma Q, Jiao C, Liu J, et al
    Recombinant duck enteritis virus harboring the hemagglutinin genes of influenza virus rapidly induces specific cellular immunity in ducks.
    J Virol. 2025 Dec 30:e0201425. doi: 10.1128/jvi.02014.
    PubMed     Abstract available
    
    
    
59. DIEGO JG-B, Arranz-Herrero J, Laghlali G, Burgess E, et al
    Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice.
    J Virol. 2025 Dec 29:e0177425. doi: 10.1128/jvi.01774.
    PubMed     Abstract available
    
    
    November 2025
60. SAUL S, Dahal B, Luongo C, Liu X, et al
    Intranasal bovine/human parainfluenza virus 3 vaccine candidates expressing human metapneumovirus wild-type or pre-fusion F protein elicit protective immunity against human metapneumovirus in hamsters.
    J Virol. 2025 Nov 25:e0114525. doi: 10.1128/jvi.01145.
    PubMed     Abstract available
    
    
    
61. LI Q, Mishra H, Kain KC, Wang R, et al
    The hidden threats posed by Japanese encephalitis virus genotype V.
    J Virol. 2025;99:e0164425.
    PubMed     Abstract available
    
    
    
62. NOTARIO L, Guerrero-Espinosa E, Nistal M, Lauzurica P, et al
    Thyroid hormone deficiency worsens outcomes in vaccinia virus infection.
    J Virol. 2025 Nov 20:e0129425. doi: 10.1128/jvi.01294.
    PubMed     Abstract available
    
    
    
63. SAENG-CHUTO K, Wang Z, Krueger AC, Bargeron K, et al
    A novel antiviral role of ankyrin repeat and LEM domain-containing 2 (ANKLE2) in restricting vaccinia virus through barrier to autointegration factor (BAF).
    J Virol. 2025 Nov 18:e0154925. doi: 10.1128/jvi.01549.
    PubMed     Abstract available
    
    
    
64. YAN W, Liu X, Jiang S, Li H, et al
    Emergence and characterization of historically extinct virulent genotype IV Newcastle disease virus in wild and domestic birds: genetic insights, pathogenicity, and vaccine efficacy.
    J Virol. 2025 Nov 13:e0164625. doi: 10.1128/jvi.01646.
    PubMed     Abstract available
    
    
    
65. NAITO T, Ushirogawa H, Kunishio M, Yano H, et al
    Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant.
    J Virol. 2025 Nov 13:e0139025. doi: 10.1128/jvi.01390.
    PubMed     Abstract available
    
    
    
66. WEI X-F, Zhao L, Zhao Z, Gong Y-M, et al
    Design of antibody structure-guided epitope vaccines in silico to induce potent immune responses against emerging viruses.
    J Virol. 2025 Nov 11:e0068925. doi: 10.1128/jvi.00689.
    PubMed     Abstract available
    
    
    
67. JAMIESON PJ, Shen X, Abu-Shmais AA, Wasdin PT, et al
    Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.
    J Virol. 2025 Nov 10:e0125625. doi: 10.1128/jvi.01256.
    PubMed     Abstract available
    
    
    
68. SUN Y, Xu S-J, Zhou Y, Zhang Y, et al
    A glycoprotein D-targeted lipid nanoparticle-encapsulated mRNA vaccine elicits strong protective immunity against pseudorabies virus.
    J Virol. 2025 Nov 6:e0147225. doi: 10.1128/jvi.01472.
    PubMed     Abstract available
    
    
    
69. IRELAND J, Myers D, Huang C, Allen C, et al
    Vaccination protects against COVID-associated pulmonary fibrin deposition.
    J Virol. 2025 Nov 6:e0063325. doi: 10.1128/jvi.00633.
    PubMed     Abstract available
    
    
    
70. CHANG LA, Yeung ST, Warang P, Noureddine M, et al
    Transient lung eosinophilia during breakthrough influenza infection in vaccinated mice is associated with protective and balanced Type 1/2 immune responses.
    J Virol. 2025 Nov 5:e0096525. doi: 10.1128/jvi.00965.
    PubMed     Abstract available
    
    
    October 2025
71. ZHANG D, Yuan Y, Hu G, Xie Y, et al
    Engineering a TGEV S-trimer chimera with PEDV D0-NTD generates potent neutralizing antibodies against both viruses.
    J Virol. 2025 Oct 31:e0145225. doi: 10.1128/jvi.01452.
    PubMed     Abstract available
    
    
    
72. LEI H, Xiao B, Lin X, Liang Z, et al
    Chronology of H3N2 human influenza virus surface glycoprotein adaptation from 1968 to 2019 reveals a surge of adaptation between 1997 and 2002.
    J Virol. 2025 Oct 31:e0132925. doi: 10.1128/jvi.01329.
    PubMed     Abstract available
    
    
    
73. RZYMSKI P, Poniedzialek B, Zarebska-Michaluk D, Tomasiewicz K, et al
    High seroprevalence and high risk: why are older adults more prone to respiratory syncytial virus?
    J Virol. 2025;99:e0143225.
    PubMed     Abstract available
    
    
    
74. DANGI T, Li S, Penaloza-MacMaster P
    Development of a cross-protective common cold coronavirus vaccine.
    J Virol. 2025 Oct 22:e0152625. doi: 10.1128/jvi.01526.
    PubMed     Abstract available
    
    
    
75. WANG W, Du P, Zhao Y, Liang Y, et al
    Biomimetic nanovaccines with self-adjuvant effects induced broad-spectrum neutralizing antibodies against SARS-CoV-2 infection in rodents.
    J Virol. 2025 Oct 10:e0031525. doi: 10.1128/jvi.00315.
    PubMed     Abstract available
    
    
    
76. LAI DC, Nguyen TN, Trinh GP, Steffen D, et al
    Lipid nanoparticle-encapsulated DNA vaccine induces balanced antibody and T-cell responses in pigs with maternally derived antibodies.
    J Virol. 2025 Oct 9:e0112325. doi: 10.1128/jvi.01123.
    PubMed     Abstract available
    
    
    
77. BESSEY TK, Wang Y, Moon S-S, Sanchez-Tacuba L, et al
    Mutations of two amino acids in VP5 mediate the attenuation of human rotavirus vaccine: evidence from in vitro and in vivo studies.
    J Virol. 2025 Oct 8:e0106725. doi: 10.1128/jvi.01067.
    PubMed     Abstract available
    
    
    
78. PAN Z, Jiang L, Chen Y, Peng H, et al
    Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations.
    J Virol. 2025 Oct 3:e0109925. doi: 10.1128/jvi.01099.
    PubMed     Abstract available
    
    
    September 2025
79. SUN L, Huang M, Feng S, Zhang W, et al
    Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses.
    J Virol. 2025 Sep 30:e0120925. doi: 10.1128/jvi.01209.
    PubMed     Abstract available
    
    
    
80. ZHOU J, Cai S, Huang H, Yang F, et al
    LPS/TLR4-activated M1-polarized macrophage-derived exosomes enhance IBV vaccine efficacy in chickens.
    J Virol. 2025 Sep 23:e0115625. doi: 10.1128/jvi.01156.
    PubMed     Abstract available
    
    
    
81. PENG G, Zhao X, Zou X, Zhang H, et al
    An attenuated African swine fever virus with deletions of the CD2v and A137R genes offers complete protection against homologous challenge in pigs.
    J Virol. 2025;99:e0026225.
    PubMed     Abstract available
    
    
    
82. QU Y, Li J, Deng H, Wang Y, et al
    Viroporins: emerging viral infection mechanisms and therapeutic targets.
    J Virol. 2025;99:e0103825.
    PubMed     Abstract available
    
    
    
83. PAPPAS C, Brock N, Belser JA, Kieran TJ, et al
    Identification of clinical and virological correlates associated with influenza A candidate vaccine virus (CVV) attenuation in a ferret model.
    J Virol. 2025 Sep 17:e0102325. doi: 10.1128/jvi.01023.
    PubMed     Abstract available
    
    
    
84. CAO M, Li Y, Song X, Lu Z, et al
    Broad-spectrum vaccines against various and evolving viruses: from antigen design to nanoparticle delivery.
    J Virol. 2025 Sep 12:e0099725. doi: 10.1128/jvi.00997.
    PubMed     Abstract available
    
    
    
85. FAN W, Zeng X, Chen Y, Yu Q, et al
    A recombinant Marek's disease vaccine candidate provides complete protection against infectious bursal disease virus and H9 subtype avian influenza virus in chickens.
    J Virol. 2025 Sep 11:e0114925. doi: 10.1128/jvi.01149.
    PubMed     Abstract available
    
    
    
86. JIAO Z, Li J, Wang P, Yan Y, et al
    Mutations in feline infectious peritonitis virus nonstructural protein 14/16 methyltransferase attenuate the pathogenicity of the virus in cats.
    J Virol. 2025 Sep 9:e0083925. doi: 10.1128/jvi.00839.
    PubMed     Abstract available
    
    
    
87. HAGA Y, Babu E P, Swiderska-Syn M, Reagan EK, et al
    Hepatitis C virus modified (S)E2(F442NYT)-mRNA-LNP candidate vaccine promotes helper CXCR5(+)T cells.
    J Virol. 2025 Sep 5:e0135525. doi: 10.1128/jvi.01355.
    PubMed     Abstract available
    
    
    
88. OOM AL, Wilson KK, Yonatan M, Rettig S, et al
    Correction for Oom et al., "The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response".
    J Virol. 2025 Sep 4:e0087225. doi: 10.1128/jvi.00872.
    PubMed    
    
    
    August 2025
89. CHATURBHUJ DN, Sliepen K, Cupo A, Steinberg B, et al
    A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers.
    J Virol. 2025 Aug 27:e0091325. doi: 10.1128/jvi.00913.
    PubMed     Abstract available
    
    
    
90. HU Z, Tian S, Zhou Y, Wang Y, et al
    Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses.
    J Virol. 2025 Aug 26:e0090325. doi: 10.1128/jvi.00903.
    PubMed     Abstract available
    
    
    
91. HE Q, Zou Y, Yu B, Yuan Q, et al
    A novel nanoparticle vaccine, based on S1-CTD, elicits robust protective immune responses against porcine deltacoronavirus.
    J Virol. 2025 Aug 21:e0067425. doi: 10.1128/jvi.00674.
    PubMed     Abstract available
    
    
    
92. LIU J, Xia Y, Tian C, Chen Z, et al
    E2-based mRNA vaccine encapsulated in lipid nanoparticles protects pigs against classical swine fever virus.
    J Virol. 2025 Aug 21:e0097825. doi: 10.1128/jvi.00978.
    PubMed     Abstract available
    
    
    
93. ZHANG H, Deng X, Dai R, Fu J, et al
    Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.
    J Virol. 2025 Aug 21:e0068825. doi: 10.1128/jvi.00688.
    PubMed     Abstract available
    
    
    
94. HU J, Zheng H, Ran W, Wang X, et al
    Mucosal vaccination with long-form TSLP induces migratory cDC1-mediated adaptive immunity against SARS-CoV-2 infection.
    J Virol. 2025 Aug 19:e0123125. doi: 10.1128/jvi.01231.
    PubMed     Abstract available
    
    
    
95. ZHANG C, Zhou Y-C, Song W-Y, Liu X-X, et al
    Rationally designed self-assembled peptide nanofibers provoke robust humoral immunity against nervous necrosis virus.
    J Virol. 2025;99:e0031925.
    PubMed     Abstract available
    
    
    
96. CHIU H-J, Wang H-C, Chang W
    Structural dissection of vaccinia G9 identifies residues essential for membrane fusion and complex assembly.
    J Virol. 2025 Aug 18:e0072325. doi: 10.1128/jvi.00723.
    PubMed     Abstract available
    
    
    
97. GUO S, Ru Y, Zhang H, Xue J, et al
    An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development.
    J Virol. 2025 Aug 14:e0047825. doi: 10.1128/jvi.00478.
    PubMed     Abstract available
    
    
    
98. DZIMIANSKI JV, Nagashima KA, Cruz JM, Sautto GA, et al
    Assessing the structural boundaries of broadly reactive antibody interactions with diverse H3 influenza hemagglutinin proteins.
    J Virol. 2025 Aug 14:e0045325. doi: 10.1128/jvi.00453.
    PubMed     Abstract available
    
    
    
99. SOWNTHIRARAJAN B, Mason M, Loganathan G, Manivasagam S, et al
    A versatile H5N1-VSV platform for safe influenza virus research applications.
    J Virol. 2025 Aug 8:e0097525. doi: 10.1128/jvi.00975.
    PubMed     Abstract available
    
    
    
100. YU R, Bai Y, Zhang L, Zhou P, et al
     Single self-cleaving mRNA vaccine expressing multiple viral structural proteins elicits robust immune responses and protects nursing piglets against PDCoV infection.
     J Virol. 2025 Aug 6:e0084925. doi: 10.1128/jvi.00849.
     PubMed     Abstract available
     
     
     
101. BAI Y-Z, Xu H, Liu Y-G, Sun Y, et al
     Nsp2 replicase-mediated viral uncoating in porcine alveolar macrophages contributes to the attenuation of PRRSV-2 live attenuated vaccine.
     J Virol. 2025 Aug 4:e0063625. doi: 10.1128/jvi.00636.
     PubMed     Abstract available
     
     
     
102. MBOKO WP, Wang Y, Cao W, Sayedahmed EE, et al
     Trained ILCs confer adaptive immunity-independent protection against influenza.
     J Virol. 2025 Aug 4:e0053225. doi: 10.1128/jvi.00532.
     PubMed     Abstract available
     
     
     July 2025
103. DONG J, Yue Luo S, Smyth S, Melvie G, et al
     The vaccinia virus protein, C16, promotes the ubiquitylation and relocalization of the antiviral E3 ubiquitin-ligase, TRIM25.
     J Virol. 2025 Jul 28:e0089825. doi: 10.1128/jvi.00898.
     PubMed     Abstract available
     
     
     
104. TOHMA K, Ford-Siltz LA, Kendra JA, Parra GI, et al
     Manipulation of immunodominant variable epitopes of norovirus capsid protein elicited cross-blocking antibodies to different GII.4 variants despite the low potency of the polyclonal sera.
     J Virol. 2025;99:e0061125.
     PubMed     Abstract available
     
     
     
105. LEONARD RA, Spurrier MA, Skavicus S, Luo Z, et al
     Development of DNA and mRNA-LNP vaccines against an H5N1 clade 2.3.4.4b influenza virus.
     J Virol. 2025 Jul 16:e0079525. doi: 10.1128/jvi.00795.
     PubMed     Abstract available
     
     
     
106. CARLOCK MA, Pierce SR, Ross TM
     Breadth of antibody activity elicited by an influenza B hemagglutinin vaccine is influenced by pre-existing immune responses to influenza B viruses.
     J Virol. 2025 Jul 15:e0070525. doi: 10.1128/jvi.00705.
     PubMed     Abstract available
     
     
     
107. WINSTON SM, Wiggins KB, Schultz-Cherry S, Davidoff AM, et al
     Teaching an old vector new tricks: the surprising versatility of AAV vaccines.
     J Virol. 2025 Jul 14:e0073025. doi: 10.1128/jvi.00730.
     PubMed     Abstract available
     
     
     
108. HENG W, Zang D, Li R, Jiang Q, et al
     A novel replication-deficient FCV vaccine provides strong immune protection in cats.
     J Virol. 2025 Jul 8:e0009325. doi: 10.1128/jvi.00093.
     PubMed     Abstract available
     
     
     June 2025
109. SONG Q, Yang H, Zhu H, Hu Y, et al
     Hydrophobic residue substitutions enhance the stability and in vivo immunogenicity of respiratory syncytial virus fusion protein.
     J Virol. 2025;99:e0008725.
     PubMed     Abstract available
     
     
     
110. HARRIS C, Kapingidza AB, San JE, Christopher J, et al
     Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.
     J Virol. 2025 Jun 13:e0046525. doi: 10.1128/jvi.00465.
     PubMed     Abstract available
     
     
     
111. LIU M, Aryal B, Niu X, Wang Q, et al
     Engineering a recombination-resistant live attenuated vaccine candidate with suppressed interferon antagonists for PEDV.
     J Virol. 2025 Jun 12:e0045125. doi: 10.1128/jvi.00451.
     PubMed     Abstract available
     
     
     
112. SCHLEISS MR, Fernandez-Alarcon C, Bierle CJ, Geballe AP, et al
     Replication-deficient whole-virus vaccines against cytomegalovirus induce protective immunity in a guinea pig congenital infection model.
     J Virol. 2025 Jun 11:e0020725. doi: 10.1128/jvi.00207.
     PubMed     Abstract available
     
     
     
113. COGGON A, Lopes S, Simon G, Arendsee Z, et al
     Quantifying the zoonotic risk profile of European influenza A viruses in swine from 2010 to 2020 inclusive.
     J Virol. 2025 Jun 4:e0030625. doi: 10.1128/jvi.00306.
     PubMed     Abstract available
     
     
     May 2025
114. KARTHIGEYAN KP, Connors M, Binuya CR, Gross M, et al
     A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits humoral immunity similar to that of postfusion gB in mice.
     J Virol. 2025 May 8:e0217824. doi: 10.1128/jvi.02178.
     PubMed     Abstract available
     
     
     
115. LUGANO D, Mwangi K, Mware B, Kibet G, et al
     Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population.
     J Virol. 2025 May 6:e0048225. doi: 10.1128/jvi.00482.
     PubMed     Abstract available
     
     
     April 2025
116. LE CTT, Kim K-H, Raha JR, Bhatnagar N, et al
     Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination.
     J Virol. 2025 Apr 23:e0229424. doi: 10.1128/jvi.02294.
     PubMed     Abstract available
     
     
     
117. LI Y, Yang S, Qian J, Liu S, et al
     Molecular characteristics of the immune escape of coronavirus PEDV under the pressure of vaccine immunity.
     J Virol. 2025 Apr 16:e0219324. doi: 10.1128/jvi.02193.
     PubMed     Abstract available
     
     
     
118. THIONO DJ, Samaras D, Phan TTN, Zhu DR, et al
     Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domains.
     J Virol. 2025 Apr 16:e0022925. doi: 10.1128/jvi.00229.
     PubMed     Abstract available
     
     
     
119. KAWAKITA T, Sekiya T, Kameda Y, Nomura N, et al
     ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4(+) and CD8(+) T-cell responses and neutralizing antibody induction.
     J Virol. 2025 Apr 15:e0229024. doi: 10.1128/jvi.02290.
     PubMed     Abstract available
     
     
     
120. LOU Y-N, Sun M-X, Li K, Xiong X-C, et al
     A single residue in domain II of envelope protein of yellow fever virus is critical for neutralization sensitivity.
     J Virol. 2025;99:e0177024.
     PubMed     Abstract available
     
     
     
121. CHENTOUFI AA, Prakash S, Vahed H, Karan S, et al
     A tissue-targeted prime/pull/keep therapeutic herpes simplex virus vaccine protects against recurrent ocular herpes infection and disease in HLA-A*0201 transgenic rabbits.
     J Virol. 2025 Apr 10:e0013525. doi: 10.1128/jvi.00135.
     PubMed     Abstract available
     
     
     March 2025
122. BLASS E, Colarusso A, Aid M, Larocca RA, et al
     Early spatiotemporal evolution of the immune response elicited by adenovirus serotype 26 vector vaccination in mice.
     J Virol. 2025 Mar 31:e0024725. doi: 10.1128/jvi.00247.
     PubMed     Abstract available
     
     
     
123. OOM AL, Wilson KK, Yonatan M, Rettig S, et al
     The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response.
     J Virol. 2025 Mar 31:e0025325. doi: 10.1128/jvi.00253.
     PubMed     Abstract available
     
     
     
124. JANA ID, Kanjo K, Roy S, Bhasin M, et al
     Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
     J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051.
     PubMed     Abstract available
     
     
     
125. LI P, Faraone JN, Hsu CC, Chamblee M, et al
     Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
     J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242.
     PubMed     Abstract available
     
     
     
126. BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al
     A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
     J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990.
     PubMed     Abstract available
     
     
     
127. BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al
     Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants.
     J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989.
     PubMed     Abstract available
     
     
     
128. MLINGO TAM, Theron J, Mokoena NB
     Plasmid DNA-based reverse genetics as a platform for manufacturing of bluetongue vaccine.
     J Virol. 2025 Mar 6:e0013925. doi: 10.1128/jvi.00139.
     PubMed     Abstract available
     
     
     
129. HU H, Zhang Y, Zheng H, Zhao X, et al
     Thymic stromal lymphopoietin improves protective immunity of the SARS-CoV-2 subunit vaccine by inducing dendritic cell-dependent germinal center response.
     J Virol. 2025 Mar 4:e0232324. doi: 10.1128/jvi.02323.
     PubMed     Abstract available
     
     
     
130. KARL V, Hofmann M, Thimme R
     Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination.
     J Virol. 2025 Mar 3:e0135024. doi: 10.1128/jvi.01350.
     PubMed     Abstract available
     
     
     February 2025
131. ABBO SR, Yan K, Geertsema C, Hick TAH, et al
     Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage.
     J Virol. 2025 Feb 27:e0232224. doi: 10.1128/jvi.02322.
     PubMed     Abstract available
     
     
     
132. KEEP S, Foldes K, Dowgier G, Freimanis G, et al
     Recombinant infectious bronchitis virus containing mutations in non-structural proteins 10, 14, 15, and 16 and within the macrodomain provides complete protection against homologous challenge.
     J Virol. 2025 Feb 27:e0166324. doi: 10.1128/jvi.01663.
     PubMed     Abstract available
     
     
     
133. LI W, Hangalapura BN, van den Elzen P, van den Born E, et al
     Spike gene variability in porcine epidemic diarrhea virus as a determinant for virulence.
     J Virol. 2025 Feb 26:e0216524. doi: 10.1128/jvi.02165.
     PubMed     Abstract available
     
     
     
134. CHEN C-X, Wang X, Su W, Tian Y, et al
     Changes in the dynamic characteristics of G-protein can alter the immune-protection efficacy of rabies virus vaccine.
     J Virol. 2025 Feb 21:e0195424. doi: 10.1128/jvi.01954.
     PubMed     Abstract available
     
     
     
135. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
     Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
     J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
     PubMed     Abstract available
     
     
     January 2025
136. SAMAAN P, Korosec CS, Budylowski P, Chau SLL, et al
     mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-gamma and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.
     J Virol. 2025 Jan 31:e0168524. doi: 10.1128/jvi.01685.
     PubMed     Abstract available
     
     
     
137. ZHAO B, Sun Z, Wang S, Shi Z, et al
     Structural basis of different neutralization capabilities of monoclonal antibodies against H7N9 virus.
     J Virol. 2025;99:e0140024.
     PubMed     Abstract available
     
     
     
138. SADLER HL, Rijal P, Tan TK, Townsend ARM, et al
     A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.
     J Virol. 2025 Jan 27:e0033124. doi: 10.1128/jvi.00331.
     PubMed     Abstract available
     
     
     
139. KENNEDY PGE, Grose C
     Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination.
     J Virol. 2025 Jan 17:e0181624. doi: 10.1128/jvi.01816.
     PubMed     Abstract available
     
     
     
140. NAGHIBOSADAT M, Babuadze GG, Pei Y, Hurst J, et al
     Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models.
     J Virol. 2025 Jan 16:e0139024. doi: 10.1128/jvi.01390.
     PubMed     Abstract available
     
     
     
141. DSOUZA L, Pant A, Pope B, Yang Z, et al
     Vaccinia growth factor-dependent modulation of the mTORC1-CAD axis upon nutrient restriction.
     J Virol. 2025 Jan 16:e0211024. doi: 10.1128/jvi.02110.
     PubMed     Abstract available
     
     
     December 2024
142. LV H, Teo QW, Lee C-CD, Liang W, et al
     Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model.
     J Virol. 2024 Dec 5:e0169524. doi: 10.1128/jvi.01695.
     PubMed     Abstract available
     
     
     November 2024
143. LI C, Culhane MR, Schroeder DC, Cheeran MC-J, et al
     Quantifying the impact of vaccination on transmission and diversity of influenza A variants in pigs.
     J Virol. 2024 Nov 12:e0124524. doi: 10.1128/jvi.01245.
     PubMed     Abstract available
     
     
     
144. JIMENEZ-CABELLO L, Utrilla-Trigo S, Rodriguez-Sabando K, Carra-Valenzuela A, et al
     Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.
     J Virol. 2024 Nov 7:e0168724. doi: 10.1128/jvi.01687.
     PubMed     Abstract available
     
     
     
145. CHEN D, Zhang W, Xiao B, Xu B, et al
     Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
     J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
     PubMed     Abstract available
     
     
     
146. DAI W, Xing M, Sun L, Lv L, et al
     Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and humoral immune responses in a TLR9- and type I IFN-dependent pathway.
     J Virol. 2024 Nov 4:e0169924. doi: 10.1128/jvi.01699.
     PubMed     Abstract available
     
     
     October 2024
147. PANT A, Brahim Belhaouari D, Dsouza L, Yang Z, et al
     Stimulation of neutral lipid synthesis via viral growth factor signaling and ATP citrate lyase during vaccinia virus infection.
     J Virol. 2024 Oct 30:e0110324. doi: 10.1128/jvi.01103.
     PubMed     Abstract available
     
     
     
148. CAILLAVA AJ, Alfonso V, Tejerina Cibello M, Demaria MA, et al
     A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.
     J Virol. 2024 Oct 23:e0101724. doi: 10.1128/jvi.01017.
     PubMed     Abstract available
     
     
     
149. ZHANG D, Xie Y, Liao Q, Jiao Z, et al
     Development of a safe and broad-spectrum attenuated PEDV vaccine candidate by S2 subunit replacement.
     J Virol. 2024 Oct 15:e0042924. doi: 10.1128/jvi.00429.
     PubMed     Abstract available
     
     
     
150. WANG W, Bhushan G, Paz S, Stauft CB, et al
     Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
     J Virol. 2024 Oct 4:e0094824. doi: 10.1128/jvi.00948.
     PubMed     Abstract available
     
     
     
151. DO THT, Wille M, Wheatley AK, Koutsakos M, et al
     Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase.
     J Virol. 2024 Oct 3:e0118624. doi: 10.1128/jvi.01186.
     PubMed     Abstract available
     
     
     September 2024
152. HAMELE CE, Luo Z, Leonard RA, Spurrier MA, et al
     Headless hemagglutinin-containing influenza viral particles direct immune responses toward more conserved epitopes.
     J Virol. 2024 Sep 26:e0116624. doi: 10.1128/jvi.01166.
     PubMed     Abstract available
     
     
     
153. LOES AN, Tarabi RAL, Huddleston J, Touyon L, et al
     High-throughput sequencing-based neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1 influenza strains.
     J Virol. 2024 Sep 24:e0068924. doi: 10.1128/jvi.00689.
     PubMed     Abstract available
     
     
     
154. SONG X, Li Y, Wang C, Zhao Y, et al
     Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross-protection.
     J Virol. 2024 Sep 10:e0130924. doi: 10.1128/jvi.01309.
     PubMed     Abstract available
     
     
     
155. AGRAWAL P, Knudsen ML, MacCamy A, Hurlburt NK, et al
     Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.
     J Virol. 2024 Sep 6:e0074424. doi: 10.1128/jvi.00744.
     PubMed     Abstract available
     
     
     
156. SOUDANI N, Bricker TL, Darling T, Seehra K, et al
     Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
     J Virol. 2024 Sep 4:e0052824. doi: 10.1128/jvi.00528.
     PubMed     Abstract available
     
     
     August 2024
157. YING B, Liang C-Y, Desai P, Scheaffer SM, et al
     Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
     J Virol. 2024 Aug 28:e0057424. doi: 10.1128/jvi.00574.
     PubMed     Abstract available
     
     
     
158. GOODWIN E, Gibbs JS, Yewdell JW, Eisenlohr LC, et al
     Influenza virus antibodies inhibit antigen-specific de novo B cell responses in mice.
     J Virol. 2024 Aug 28:e0076624. doi: 10.1128/jvi.00766.
     PubMed     Abstract available
     
     
     
159. WANG G, Verma AK, Guan X, Bu F, et al
     Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
     J Virol. 2024 Aug 27:e0037624. doi: 10.1128/jvi.00376.
     PubMed     Abstract available
     
     
     
160. UNO N, Ebensen T, Guzman CA, Ross TM, et al
     Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses.
     J Virol. 2024 Aug 22:e0035424. doi: 10.1128/jvi.00354.
     PubMed     Abstract available
     
     
     
161. MOSS WJ, Griffin DE
     What's going on with measles?
     J Virol. 2024;98:e0075824.
     PubMed     Abstract available
     
     
     
162. LI J, Xiao L, Chen Z, Fan L, et al
     A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets.
     J Virol. 2024 Aug 19:e0053524. doi: 10.1128/jvi.00535.
     PubMed     Abstract available
     
     
     
163. MU Z, Whitley J, Martik D, Sutherland L, et al
     Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.
     J Virol. 2024 Aug 13:e0013724. doi: 10.1128/jvi.00137.
     PubMed     Abstract available
     
     
     July 2024
164. WIGGINS KB, Winston SM, Reeves IL, Gaevert J, et al
     rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose.
     J Virol. 2024 Jul 30:e0078124. doi: 10.1128/jvi.00781.
     PubMed     Abstract available
     
     
     
165. NELSON GW, van Duijn J, Yuki Y, Pau MG, et al
     Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.
     J Virol. 2024 Jul 24:e0028124. doi: 10.1128/jvi.00281.
     PubMed     Abstract available
     
     
     
166. LINGEMANN M, Amaro-Carambot E, Lamirande EW, Pierson TC, et al
     Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles.
     J Virol. 2024;98:e0068124.
     PubMed     Abstract available
     
     
     
167. PORTUGAL R, Goldswain H, Moore R, Tully M, et al
     Six adenoviral vectored African swine fever virus genes protect against fatal disease caused by genotype I challenge.
     J Virol. 2024;98:e0062224.
     PubMed     Abstract available
     
     
     
168. KOTAKI T, Kanai Y, Onishi M, Minami S, et al
     Generation of single-round infectious rotavirus with a mutation in the intermediate capsid protein VP6.
     J Virol. 2024;98:e0076224.
     PubMed     Abstract available
     
     
     
169. MCMILLEN CM, Megli C, Radisic R, Skvarca LB, et al
     Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.
     J Virol. 2024 Jul 17:e0098324. doi: 10.1128/jvi.00983.
     PubMed     Abstract available
     
     
     
170. ZHANG L, Yu R, Wang L, Zhang Z, et al
     Serial cell culture passaging in vitro led to complete attenuation and changes in the characteristic features of a virulent porcine deltacoronavirus strain.
     J Virol. 2024 Jul 16:e0064524. doi: 10.1128/jvi.00645.
     PubMed     Abstract available
     
     
     
171. RICHARDSON SI, Mzindle N, Motlou T, Manamela NP, et al
     SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcgammaRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
     J Virol. 2024 Jul 2:e0067824. doi: 10.1128/jvi.00678.
     PubMed     Abstract available
     
     
     June 2024
172. ZHU J, Wang Z, Li Y, Zhang Z, et al
     Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
     J Virol. 2024 Jun 14:e0052124. doi: 10.1128/jvi.00521.
     PubMed     Abstract available
     
     
     
173. BOOPATHY AV, Nekkalapudi A, Sung J, Schulha S, et al
     Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.
     J Virol. 2024 Jun 3:e0029424. doi: 10.1128/jvi.00294.
     PubMed     Abstract available
     
     
     
174. LU J, Liu J, Wu Y, He X, et al
     A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses.
     J Virol. 2024 Jun 3:e0076924. doi: 10.1128/jvi.00769.
     PubMed     Abstract available
     
     
     May 2024
175. CARTER DM, Darby CA, Lefoley BC, Crevar CJ, et al
     Correction for Carter et al., "Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses".
     J Virol. 2024 May 31:e0181323. doi: 10.1128/jvi.01813.
     PubMed    
     
     
     
176. DOETS K, Pijlman GP
     Subgenomic flavivirus RNA as key target for live-attenuated vaccine development.
     J Virol. 2024 May 29:e0010023. doi: 10.1128/jvi.00100.
     PubMed     Abstract available
     
     
     
177. HASHIZUME M, Takashima A, Iwasaki M
     An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
     J Virol. 2024 May 20:e0057824. doi: 10.1128/jvi.00578.
     PubMed     Abstract available
     
     
     April 2024
178. THORESEN D, Matsuda K, Urakami A, Ngwe Tun MM, et al
     A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
     J Virol. 2024 Apr 22:e0023924. doi: 10.1128/jvi.00239.
     PubMed     Abstract available
     
     
     
179. FAN Y-C, Chen J-M, Chen Y-Y, Ke Y-D, et al
     Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity.
     J Virol. 2024;98:e0177323.
     PubMed     Abstract available
     
     
     
180. PEREZ DR
     A devastating blow: personal reflections on Argentina's scientific decline.
     J Virol. 2024 Apr 16:e0054924. doi: 10.1128/jvi.00549.
     PubMed     Abstract available
     
     
     
181. ISHIMARU H, Nishimura M, Shigematsu H, Marini MI, et al
     Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
     J Virol. 2024 Apr 16:e0041624. doi: 10.1128/jvi.00416.
     PubMed     Abstract available
     
     
     
182. TANG X, Li S, Zhou J, Bian X, et al
     Recombinant bivalent subunit vaccine combining truncated VP4 from P[7] and P[23] induces protective immunity against prevalent porcine rotaviruses.
     J Virol. 2024 Apr 9:e0021224. doi: 10.1128/jvi.00212.
     PubMed     Abstract available
     
     
     
183. QUADIRI A, Prakash S, Dhanushkodi NR, Singer M, et al
     Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4(+) and CD8(+) T cells and protects against recurrent
     J Virol. 2024 Apr 8:e0159623. doi: 10.1128/jvi.01596.
     PubMed     Abstract available
     
     
     
184. MANTEL N, Piras-Douce F, Chautard E, Marcos-Lopez E, et al
     Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
     J Virol. 2024 Apr 3:e0151623. doi: 10.1128/jvi.01516.
     PubMed     Abstract available
     
     
     
185. BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al
     A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
     J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693.
     PubMed     Abstract available
     
     
     
186. NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al
     A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
     J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762.
     PubMed     Abstract available
     
     
     
187. ZHU Z, Han Y, Gong M, Sun B, et al
     Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry.
     J Virol. 2024 Apr 1:e0195723. doi: 10.1128/jvi.01957.
     PubMed     Abstract available
     
     
     March 2024
188. WU K, Hou YJ, Makrinos D, Liu R, et al
     Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
     J Virol. 2024 Mar 25:e0160323. doi: 10.1128/jvi.01603.
     PubMed     Abstract available
     
     
     
189. NUNBERG JH, Westover JB, York J, Jung KH, et al
     Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC.
     J Virol. 2024 Mar 20:e0011224. doi: 10.1128/jvi.00112.
     PubMed     Abstract available
     
     
     
190. MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al
     The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.
     J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
     PubMed     Abstract available
     
     
     February 2024
191. GEORGANA I, Scutts SR, Gao C, Lu Y, et al
     Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4.
     J Virol. 2024 Feb 27:e0148523. doi: 10.1128/jvi.01485.
     PubMed     Abstract available
     
     
     
192. JOSHI VR, Claiborne DT, Pack ML, Power KA, et al
     A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
     J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720.
     PubMed     Abstract available
     
     
     
193. KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al
     Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping.
     J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
     PubMed     Abstract available
     
     
     
194. SHINGAI M, Iida S, Kawai N, Kawahara M, et al
     Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire.
     J Virol. 2024 Feb 7:e0199523. doi: 10.1128/jvi.01995.
     PubMed     Abstract available
     
     
     
195. LI H, Sun H, Tao M, Han Q, et al
     Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
     J Virol. 2024 Feb 2:e0112923. doi: 10.1128/jvi.01129.
     PubMed     Abstract available
     
     
     
196. HSIEH M-S, Hsu C-W, Liao H-C, Lin C-L, et al
     SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
     J Virol. 2024 Feb 1:e0154623. doi: 10.1128/jvi.01546.
     PubMed     Abstract available
     
     
     January 2024
197. ROWE T, Davis W, Wentworth DE, Ross T, et al
     Differential interferon responses to influenza A and B viruses in primary ferret respiratory epithelial cells.
     J Virol. 2024 Jan 31:e0149423. doi: 10.1128/jvi.01494.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum